Q-omics provides the consensus-scored TXNL4A profile across patient tissues and cancer cell-line models. TXNL4A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TXNL4A is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TXNL4A protein abundance shows 20,879 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where TXNL4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TXNL4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TXNL4A survival associations across molecular data types. TXNL4A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TXNL4A RNA expression–survival associations across cancer types. High TXNL4A expression shows unfavorable associations in ACC, LIHC, UVM, SKCM, UCS and COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TXNL4A RNA expression.
This table summarizes TXNL4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TXNL4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TXNL4A shows higher tumor expression in KIRC, LIHC, STAD, BLCA, LUAD and UCEC. The KIRC box plot shows higher TXNL4A RNA expression in tumor versus normal tissue (log2 FC = +0.447, t-test p < 0.001).
This table shows molecular features associated with TXNL4A in patient tissues and cancer cell lines. In patient samples, TXNL4A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TXNL4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
